🔗 Share this article

Given that America proceeds with unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccines throughout the pandemic and has zeroed in on potential fatalities following COVID-19 vaccination in her brief position at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Agency leaders had intended to reveal major changes to the childhood immunization program recently, synchronizing the US with the Danish national calendar, sources say – a significant shift that would place the US at odds with a large portion of the international standard with little proof for public health gain. This reveal has been postponed until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to run the office this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing some pediatric shot schedules in the US to become more similar to the Danish model, a country with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible experience in drug development, approval processes or management, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who headed CBER have had.”

CDER has an enormous range of responsibilities at the agency, she stated.

“The public just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one have to be managed,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to bite you.”

There is also, a significant administrative element to the position, which supervises over 5,000 employees. “It is a enormous administrative position, if you execute it properly,” she said.

Agency Reaction and Contentious Policies

When asked about questions about Høeg’s fitness for the role and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “questions stem from incorrect assumptions”.

“This background aligns with the responsibilities of her role,” the spokesperson explained, citing the months Høeg spent guiding the agency head on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a disputed expedited medication authorization process that allegedly worried her preceding directors. “By what process are these therapies being selected for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer regulations of pharmaceuticals, except for shots.”

Public History on Vaccines

Concerning immunizations, Høeg has a more documented, if concerning, track record, critics said. She published a research paper using non-validated public submissions to determine the frequency of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current government featured altering guidelines for novel immunizations and halting “non-essential” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of preventing teenage boys from getting Covid vaccinations.

“She is an complete dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the evidence in a highly misleading, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg aligned with other contrarians, {like|